- Home
- MLM vs ARGX Comparison
MLM vs ARGX Comparison
Compare MLM & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLM
- ARGX
- Stock Information
- Founded
- MLM 1993
- ARGX 2008
- Country
- MLM United States
- ARGX Netherlands
- Employees
- MLM N/A
- ARGX N/A
- Industry
- MLM Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MLM Industrials
- ARGX Health Care
- Exchange
- MLM Nasdaq
- ARGX Nasdaq
- Market Cap
- MLM 32.1B
- ARGX 37.3B
- IPO Year
- MLM 1994
- ARGX 2017
- Fundamental
- Price
- MLM $543.11
- ARGX $640.52
- Analyst Decision
- MLM Strong Buy
- ARGX Strong Buy
- Analyst Count
- MLM 15
- ARGX 20
- Target Price
- MLM $645.86
- ARGX $653.11
- AVG Volume (30 Days)
- MLM 393.4K
- ARGX 258.1K
- Earning Date
- MLM 02-12-2025
- ARGX 02-27-2025
- Dividend Yield
- MLM 0.56%
- ARGX N/A
- EPS Growth
- MLM 86.63
- ARGX N/A
- EPS
- MLM 32.12
- ARGX N/A
- Revenue
- MLM $6,513,200,000.00
- ARGX $1,908,659,000.00
- Revenue This Year
- MLM N/A
- ARGX $70.98
- Revenue Next Year
- MLM $10.22
- ARGX $51.22
- P/E Ratio
- MLM $16.85
- ARGX N/A
- Revenue Growth
- MLM N/A
- ARGX 85.56
- 52 Week Low
- MLM $490.05
- ARGX $349.86
- 52 Week High
- MLM $633.23
- ARGX $678.21
- Technical
- Relative Strength Index (RSI)
- MLM 55.21
- ARGX 52.90
- Support Level
- MLM $526.10
- ARGX $657.10
- Resistance Level
- MLM $521.97
- ARGX $678.21
- Average True Range (ATR)
- MLM 9.02
- ARGX 15.00
- MACD
- MLM 4.47
- ARGX 0.45
- Stochastic Oscillator
- MLM 96.19
- ARGX 42.20
About MLM Martin Marietta Materials Inc.
Martin Marietta Materials is one of the United States' largest producer of construction aggregates (crushed stone, sand, and gravel). In 2023, Martin Marietta sold 199 million tons of aggregates. Martin Marietta's most important markets include Texas, Colorado, North Carolina, Georgia, and Florida, accounting for most of its sales. The company also produces cement in Texas and uses its aggregates in its asphalt and ready-mixed concrete businesses. Martin's magnesia specialties business produces magnesia-based chemical products and dolomitic lime.
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.